ODI Pharma AB (“ODI” or the “Company”) hereby announces that kandol., the CBD skincare product line, will be officially launched as of...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the fourth quarter and financial year 1st of July 2020 –...

ODI Pharma AB (“ODI Pharma” or the “Company”), a producer and representative of finished pharmaceutical cannabis and cosmetics products,...

ODI Pharma AB (“ODI Pharma”) has been informed that Mr. Niclas Kappelin has acquired 20’000 shares in ODI Pharma and exceeded the...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report concerning the period July 2020 – March 2021. The report is...

In January 2021 and February 2021, ODI Pharma AB (“ODI” or the “Company”) announced the decision to expand its current business with...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2020. The report is available...

ODI Pharma AB (“ODI” or the “Company”) announces that its subsidiary ODI Pharma Polska Sp. z o.o. has finalized documentation and filed...

ODI Pharma AB (“ODI” or “the Company”) announces that the Board of Directors has decided to expand ODI’s current business with...

This is an unofficial translation of a communique from the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish....

Idag den 14 december 2020, hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July – September 2020. The report is available...

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI”) hereby publish the annual report of the fiscal year...

ODI Pharma AB (“ODI” or “the Company”), through research carried out by its subsidiary ODI Pharma Schweiz AG, announces that the Company...

This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In...

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma måndagen den 14 december 2020 kl. 10.00 på Engelbrektsgatan...

Stockholm, Sweden and Leamington, Ontario – November 2nd, 2020 – ODI Pharma AB (“ODI”, ISIN SE0013409760) today announced that, despite...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its year-end report for the period July 2019 – June 2020. The report is available...

ODI Pharma AB (“ODI” or “the Company”) gives an update regarding that a MAR label was missing in the quarterly report published 28th of...

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report for the period July 2019 – March 2020. The report is available...